Monthly Archives: April 2007

Weekly Roundup – 4/13/07

Posted on April 13, 2007 by Mark Senak

For those who are superstitious it is Friday the 13th.  Lately, for some, it seems that characterizes every day as it has been an active week on the bad news front for many.  Here in the Beltway, Congress is back … Continue reading →

Posted in Weekly Roundup | 1 Comment

U.S. Stem Cell Policy – Ceding the Competitive Edge

Posted on April 12, 2007 by Mark Senak

By a margin of 63-34, the Senate passed the Stem Cell Research Enhancement Act –  just 3 votes shy of a veto-proof bill.  A veto is promised.  We are back where we started.  Opponents claim a moral high ground that … Continue reading →

Posted in Biologics, Current Affairs, Legislation | Comments Off on U.S. Stem Cell Policy – Ceding the Competitive Edge

Scenario Planning in the Face of Trouble

Posted on April 11, 2007 by Mark Senak

It seems that there is a lot of trouble brewing lately.  Sometimes it seems events overtake us without our being able to actually strategically consider our options.  We are reactive, rather than proactive.  There are many reasons for that, not … Continue reading →

Posted in Tutorial | Comments Off on Scenario Planning in the Face of Trouble

Leaving PDUFA Alone

Posted on April 10, 2007 by Mark Senak

PDUFA IV, as has been noted here many times, is up for passage in the Congress.  For those new to it, PDUFA is the Prescription Drug Users Fee Act which, if authorized, will provide a majority of funding for FDA … Continue reading →

Posted in Legislation, PDUFA | Comments Off on Leaving PDUFA Alone

TheStreet.com Speaks – Evaluating Pharma Stock Before Approvals – A Talk with Adam Feuerstein

Posted on April 9, 2007 by Mark Senak

A few weeks ago, I noticed an excellent article by Adam Feuerstein, Senior Columnist at TheStreet.com called Putting a Value on Provenge  describing what went into the evaluation of a single biotech company when analyzing the impact of an approval … Continue reading →

Posted in Podcast | 1 Comment